NCT05636176: An ongoing trial by Novo Nordisk A/S
This trial is ongoing. It must report results 2 years, 6 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05636176 |
|---|---|
| Title | Effects of Ziltivekimab Versus Placebo on Morbidity and Mortality in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Systemic Inflammation |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | May 8, 2023 |
| Completion date | July 2, 2027 |
| Required reporting date | July 1, 2028, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | None |